GlassScriptPhysician profile
Margaret Sullivan
NPI 1134330178
$1,522.46
in general payments reported to CMS, 2019-2025
23 companies · $267 in 2025
The $267 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $95.75 · 2021: $263 · 2022: $219 · 2023: $273 · 2024: $217 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $756.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $756.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $283.09 | 2021-2025 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $279.64 | 2021-2025 | Verquvo, Steglatro, Belsomra |
| Astrazeneca Pharmaceuticals LP | $117.96 | 2019-2025 | Farxiga |
| Medtronic, INC. | $117.65 | 2022-2025 | Linq II, Cobalt Dr Mri Surescan, Symplicity G3 |
| Pfizer INC. | $100.41 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $92.40 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.11 | 2019-2024 | Jardiance |
| Scpharmaceuticals INC. | $73.80 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $56.28 | 2019-2022 | |
| Boston Scientific Corporation | $52.33 | 2020-2024 | Watchman Access System, Vigilant X4 Crt-D |
| Lilly USA, LLC | $34.59 | 2020-2022 | |
| Inspire Medical Systems, INC. | $28.83 | 2023 | Inspire |
| Amarin Pharma, INC. | $25.61 | 2019-2021 | |
| Amgen INC. | $25.27 | 2019-2021 | |
| Corcept Therapeutics | $20.07 | 2025 | Korlym |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $19.46 | 2020 | |
| Astellas Pharma US INC | $18.60 | 2025 | Veozah |
| Radius Health, INC. | $17.41 | 2019 | |
| Arbor Pharmaceuticals, INC. | $16.49 | 2021 | |
| Smith+Nephew, INC. | $15.80 | 2023 | Pico |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $12.28 | 2024 | Lifevest |
| Takeda Pharmaceuticals U.S.A., INC. | $11.81 | 2021 | |
| Glaxosmithkline, LLC. | $11.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.